Vimta Labs Limited (NSE:VIMTALABS)
India
· Delayed Price · Currency is INR 1,009.85
+35.15 (3.61%)
Jun 12, 2025, 2:30 PM IST
Vimta Labs Revenue
In the fiscal year ending March 31, 2025, Vimta Labs had annual revenue of 3.45B INR with 19.25% growth. Vimta Labs had revenue of 958.30M in the quarter ending March 31, 2025, with 87.75% growth.
Revenue
3.45B
Revenue Growth
+19.25%
P/S Ratio
6.28
Revenue / Employee
2.63M
Employees
1,315
Market Cap
21.68B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 3.45B | 557.57M | 19.25% |
| Mar 31, 2024 | 2.90B | -294.23M | -9.22% |
| Mar 31, 2023 | 3.19B | 402.99M | 14.46% |
| Mar 31, 2022 | 2.79B | 677.23M | 32.09% |
| Mar 31, 2021 | 2.11B | 298.68M | 16.49% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 525.78B |
| Divi's Laboratories | 93.60B |
| Cipla | 271.45B |
| Apollo Hospitals Enterprise | 217.94B |
| Zydus Lifesciences | 232.42B |
| Mankind Pharma | 122.07B |
| Aurobindo Pharma | 317.24B |
| Alkem Laboratories | 129.65B |
Vimta Labs News
- 6 weeks ago - Stocks to watch on April 29: Wipro, UCO Bank, Central Bank of India, Go Digit, Avenue Supermarts, Oberoi Realty, Ultratech, Vimta Labs, RBL Bank - Business Upturn
- 6 weeks ago - Vimta Labs Q4 FY25 profit rises 31% YoY; announces 1:1 bonus issue and new biologics R&D foray - Business Upturn
- 6 months ago - Vimta Labs shares surge 34% in past one month - Business Upturn